Cidara Therapeutics, Inc. (NASDAQ:CDTX) to Post FY2025 Earnings of $12.63 Per Share, HC Wainwright Forecasts

Cidara Therapeutics, Inc. (NASDAQ:CDTX) – Equities researchers at HC Wainwright boosted their FY2025 earnings estimates for shares of Cidara Therapeutics in a report issued on Thursday, April 25th. HC Wainwright analyst E. Arce now forecasts that the biotechnology company will earn $12.63 per share for the year, up from their prior forecast of $12.60. HC Wainwright has a “Buy” rating and a $120.00 price objective on the stock. The consensus estimate for Cidara Therapeutics’ current full-year earnings is ($13.00) per share. HC Wainwright also issued estimates for Cidara Therapeutics’ FY2026 earnings at $18.85 EPS and FY2027 earnings at $40.32 EPS.

CDTX has been the topic of a number of other reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Cidara Therapeutics in a report on Tuesday. Needham & Company LLC raised their price objective on shares of Cidara Therapeutics from $3.00 to $25.00 and gave the company a “buy” rating in a report on Thursday. Finally, WBB Securities restated a “strong-buy” rating and issued a $40.00 price objective on shares of Cidara Therapeutics in a report on Thursday. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $71.25.

Cidara Therapeutics Stock Down 2.8 %

Cidara Therapeutics stock opened at $12.63 on Friday. The firm has a market cap of $57.59 million, a PE ratio of -2.63 and a beta of 0.98. Cidara Therapeutics has a 52-week low of $10.00 and a 52-week high of $29.60. The company’s 50 day moving average is $15.35 and its two-hundred day moving average is $15.31.

Institutional Investors Weigh In On Cidara Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Flagship Harbor Advisors LLC acquired a new stake in Cidara Therapeutics during the 3rd quarter worth $28,000. Raymond James Financial Services Advisors Inc. raised its stake in Cidara Therapeutics by 25.2% during the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 79,119 shares of the biotechnology company’s stock worth $75,000 after acquiring an additional 15,912 shares in the last quarter. Finally, Pale Fire Capital SE acquired a new stake in Cidara Therapeutics during the 3rd quarter worth $51,000. 35.82% of the stock is currently owned by institutional investors and hedge funds.

Cidara Therapeutics Company Profile

Cidara Therapeutics, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates.